This article is more than 5 years old. Information may no longer be current.

Jetrea approved in South Korea for symptomatic vitreomacular adhesion

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Jetrea has been approved in South Korea for the treatment of symptomatic vitreomacular adhesion, according to a ThromboGenics press release.

This is the fourth country in Asia, behind Malaysia, Singapore and Taiwan, to approve the intravitreal injection.

Jetrea (ocriplasmin) 2.5 mg/mL is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion. It was approved by the U.S. Food and Drug Administration in October 2012.

Alcon commercializes Jetrea outside the United States and will launch it in South Korea.